טוען...

Gefitinib and Methotrexate to Treat Ectopic Pregnancies with a Pre-Treatment Serum hCG 1000–10,000 IU/L: Phase II Open Label, Single Arm Multi-Centre Trial()

BACKGROUND: Ectopic pregnancies are a leading cause of maternal mortality. Most are treated surgically. We evaluated the efficacy and safety of combining oral gefitinib (epidermal growth factor receptor inhibitor) with methotrexate to treat larger ectopic pregnancies. METHODS: We performed a phase I...

תיאור מלא

שמור ב:

מידע ביבליוגרפי
הוצא לאור ב:	EBioMedicine
Main Authors:	Skubisz, Monika M., Tong, Stephen, Doust, Ann, Mollison, Jill, Johns, Terrance G., Neil, Peter, Robinson, Miranda, Bhattacharya, Siladitya, Wallace, Euan, Krzys, Nicole, Colin Duncan, W., Horne, Andrew W.
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	Elsevier 2018
נושאים:	Research Paper
גישה מקוונת:	https://ncbi.nlm.nih.gov/pmc/articles/PMC6085507/ https://ncbi.nlm.nih.gov/pubmed/29941341 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ebiom.2018.06.017
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

Gefitinib and Methotrexate to Treat Ectopic Pregnancies with a Pre-Treatment Serum hCG 1000–10,000 IU/L: Phase II Open Label, Single Arm Multi-Centre Trial()

פריטים דומים

Gefitinib and Methotrexate to Treat Ectopic Pregnancies with a Pre-Treatment Serum hCG 1000–10,000 IU/L: Phase II Open Label, Single Arm Multi-Centre Trial()